Robyn Jane Macfarlane

1.1k total citations
20 papers, 424 citations indexed

About

Robyn Jane Macfarlane is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Robyn Jane Macfarlane has authored 20 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 11 papers in Cancer Research and 9 papers in Oncology. Recurrent topics in Robyn Jane Macfarlane's work include Renal cell carcinoma treatment (6 papers), Cancer Genomics and Diagnostics (6 papers) and Prostate Cancer Treatment and Research (5 papers). Robyn Jane Macfarlane is often cited by papers focused on Renal cell carcinoma treatment (6 papers), Cancer Genomics and Diagnostics (6 papers) and Prostate Cancer Treatment and Research (5 papers). Robyn Jane Macfarlane collaborates with scholars based in Canada, United States and Finland. Robyn Jane Macfarlane's co-authors include Kim N., Krisna Murti, Luke A. Selth, Joanna L. Gillis, Scott L. Townley, Villis R. Marshall, Wayne D. Tilley, Lisa M. Butler, Cheryl D. Helgason and Akira Watahiki and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Molecular Sciences.

In The Last Decade

Robyn Jane Macfarlane

19 papers receiving 414 citations

Peers

Robyn Jane Macfarlane
Shravan Sridhar United States
S. T. Kim United States
Sushma Jonna United States
S. Négrier France
Elisa Biasco Italy
Héctor Galindo Chile
Hala Girgis Canada
Christine Brennan United States
Hai‐Liang Zhang China
Claudia Lefeuvre France
Shravan Sridhar United States
Robyn Jane Macfarlane
Citations per year, relative to Robyn Jane Macfarlane Robyn Jane Macfarlane (= 1×) peers Shravan Sridhar

Countries citing papers authored by Robyn Jane Macfarlane

Since Specialization
Citations

This map shows the geographic impact of Robyn Jane Macfarlane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robyn Jane Macfarlane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robyn Jane Macfarlane more than expected).

Fields of papers citing papers by Robyn Jane Macfarlane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robyn Jane Macfarlane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robyn Jane Macfarlane. The network helps show where Robyn Jane Macfarlane may publish in the future.

Co-authorship network of co-authors of Robyn Jane Macfarlane

This figure shows the co-authorship network connecting the top 25 collaborators of Robyn Jane Macfarlane. A scholar is included among the top collaborators of Robyn Jane Macfarlane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robyn Jane Macfarlane. Robyn Jane Macfarlane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rendon, Ricardo, et al.. (2024). An in-depth analysis on the effects of body composition in patients receiving neoadjuvant chemotherapy for urothelial cell carcinoma. Canadian Urological Association Journal. 18(6). 180–184. 3 indexed citations
3.
LeBlanc, Michael, et al.. (2024). Using quality improvement frameworks to develop, implement, and evaluate a novel ambulatory oncology pharmacy practice model: A descriptive example. American Journal of Health-System Pharmacy. 81(24). 1297–1304. 1 indexed citations
4.
Kwan, Edmond M., Moira Rushton, Sébastien J. Hotte, et al.. (2023). Prospective ctDNA genotyping for treatment selection in metastatic castration-resistant prostate cancer (mCRPC): The Canadian Cancer Trials Group phase II PC-BETS umbrella study.. Journal of Clinical Oncology. 41(6_suppl). 218–218. 4 indexed citations
5.
Macfarlane, Robyn Jane, et al.. (2023). Impact of the COVID-19 Pandemic on Medical Oncology Workload: A Provincial Review. Current Oncology. 30(3). 3149–3159. 1 indexed citations
6.
N., Kim, Som D. Mukherjee, Fred Saad, et al.. (2020). Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(15_suppl). 5551–5551. 11 indexed citations
7.
Bjarnason, Georg A., Jennifer J. Knox, Christian Kollmannsberger, et al.. (2019). The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial. European Journal of Cancer. 108. 69–77. 24 indexed citations
8.
Bjarnason, Georg A., Jennifer J. Knox, Christian Kollmannsberger, et al.. (2017). Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer.. Journal of Clinical Oncology. 35(15_suppl). 4514–4514. 4 indexed citations
9.
Bjarnason, Georg A., Jennifer J. Knox, Christian Kollmannsberger, et al.. (2015). Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology. 33(15_suppl). 4555–4555. 4 indexed citations
10.
11.
Dancey, Janet, Monika K. Krzyzanowska, Diane Provencher, et al.. (2015). NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. Journal of Clinical Oncology. 33(15_suppl). 2594–2594. 2 indexed citations
12.
Hotte, Sébastien J., Elizabeth A. Eisenhauer, Anthony M. Joshua, et al.. (2013). NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 31(15_suppl). 5042–5042. 6 indexed citations
13.
Bjarnason, Georg A., Naveen S. Basappa, Jennifer J. Knox, et al.. (2013). A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.. Journal of Clinical Oncology. 31(15_suppl). TPS4594–TPS4594. 5 indexed citations
14.
Watahiki, Akira, Robyn Jane Macfarlane, Martin Gleave, et al.. (2013). Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer. International Journal of Molecular Sciences. 14(4). 7757–7770. 100 indexed citations
15.
Macfarlane, Robyn Jane, Melanie Seal, Caroline Speers, et al.. (2012). Molecular Alterations Between the Primary Breast Cancer and the Subsequent Locoregional/Metastatic Tumor. The Oncologist. 17(2). 172–178. 32 indexed citations
16.
Macfarlane, Robyn Jane, Daniel Yick Chin Heng, Wanling Xie, et al.. (2011). The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy. Cancer. 118(2). 365–370. 22 indexed citations
17.
Selth, Luke A., Scott L. Townley, Joanna L. Gillis, et al.. (2011). Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. International Journal of Cancer. 131(3). 652–661. 155 indexed citations
18.
Macfarlane, Robyn Jane & Karen A. Gelmon. (2010). Lapatinib for breast cancer: a review of the current literature. Expert Opinion on Drug Safety. 10(1). 109–121. 23 indexed citations
19.
Truong, Pauline T., et al.. (2010). Micrometastatic Node-Positive Breast Cancer: Long-Term Outcomes and Identification of High-Risk Subsets in a Large Population-Based Series. Annals of Surgical Oncology. 17(8). 2138–2146. 17 indexed citations
20.
Macfarlane, Robyn Jane & Kim N.. (2010). Novel Targeted Therapies for Prostate Cancer. Urologic Clinics of North America. 37(1). 105–119. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shravan Sridhar Breakdown of academic impact, for papers by S. T. Kim Breakdown of academic impact, for papers by Sushma Jonna Breakdown of academic impact, for papers by S. Négrier Breakdown of academic impact, for papers by Elisa Biasco Breakdown of academic impact, for papers by Héctor Galindo Breakdown of academic impact, for papers by Hala Girgis Breakdown of academic impact, for papers by Christine Brennan Breakdown of academic impact, for papers by Hai‐Liang Zhang Breakdown of academic impact, for papers by Claudia Lefeuvre
Rankless by CCL
2026